PlainPharmaWatch

CMS Open Payments · Tool

Ascend Therapeutics US, LLC vs Mevion_Medical_Systems_Inc

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Ascend Therapeutics US, LLC has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,486, versus 1,237 for the other company. Its single largest recorded recipient represents 24.8% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Ascend Therapeutics US, LLC
HHI 1,486 · top recipient 24.8%
Ranked #868 of 1,838 companies by HHI
Mevion_Medical_Systems_Inc
HHI 1,237 · top recipient 19.6%
Ranked #934 of 1,838 companies by HHI

Payment Overview

Total Payments
$74.6K
% of Industry
0.0%
Transactions
282
Avg per Transaction
$264.50
Recipients
282
Avg per Recipient
$264.50
Payment Types
5
Top Payment Type
Consulting Fee
Total Payments
$73.7K
% of Industry
0.0%
Transactions
72
Avg per Transaction
$1.0K
Recipients
71
Avg per Recipient
$1.0K
Payment Types
5
Top Payment Type
Honoraria

Highlighted values indicate the higher figure for each metric.

Total payments compared

Ascend Therapeutics US, LLC vs Mevion_Medical_Systems_Inc - total reported payments in CMS Open Payments PY2024

Ascend Therapeutics US, LLC$74.6KMevion_Medical_Systems_Inc$73.7K

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Ascend Therapeutics US, LLC

Consulting Fee $59.6K

79.9%

Honoraria $10.5K

14.1%

Food and Beverage $4.4K

5.9%

Travel and Lodging $87.05

0.1%

Gift $46.10

0.1%

Mevion_Medical_Systems_Inc

Honoraria $23.3K

74.1%

Food and Beverage $3.6K

11.4%

Consulting Fee $3.0K

9.5%

Travel and Lodging $1.6K

5.0%

Gift $10.00

0.0%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Ascend Therapeutics US, LLC

  1. 1

    STEPHEN RABIN

    $18,504.95 · 7 txns

  2. 2

    ELLIOT CAZES

    $13,002.80 · 12 txns

  3. 3

    MAUREEN WHELIHAN

    $13,000.90 · 7 txns

  4. 4

    JAMES ALAN SIMON

    $10,174.10 · 7 txns

  5. 5

    PARVEEN VAHORA

    $3,002.80 · 10 txns

Mevion_Medical_Systems_Inc

  1. 1

    NANCY J TARBELL MD

    $6,170.00 · 3 txns

  2. 2

    JEFFREY D BRADLEY MD

    $5,104.62 · 3 txns

  3. 3

    BILLY W LOO MD

    $4,939.85 · 6 txns

  4. 4

    RAHUL R PARIKH MD

    $3,158.90 · 2 txns

  5. 5

    Barnes-Jewish Hospital

    $3,000.00 · 1 txns

Summary Comparison

Metric Ascend Therapeutics US, LLC Mevion_Medical_Systems_Inc
Total Payments $74.6K $73.7K
% of Industry Total 0.0% 0.0%
Transaction Count 282 72
Avg per Transaction $264.50 $1.0K
Recipient Count 282 71
Avg per Recipient $264.50 $1.0K
Payment Type Count 5 5
Top Payment Type Consulting Fee Honoraria

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.